CD19

CD19
Name	CD19
Uniprot	P15391
Location	Chromosome 16p11.2

CD19 CD19 is a transmembrane glycoprotein expressed on the surface of B cell lineage leukocytes that functions as a coreceptor modulating antigen receptor signaling. First characterized in studies involving monoclonal antibodies from groups associated with César Milstein, Georges Köhler, and laboratories at Cambridge University and The Rockefeller University, CD19 has been central to research linking cellular immunology, clinical hematology, and therapeutic biotechnology. Its clinical relevance spans diagnostics used by laboratories such as Mayo Clinic and translational programs at institutions like Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Center.

Structure and expression

CD19 is a 95 kDa type I transmembrane protein encoded on human chromosome 16p11.2 with two extracellular immunoglobulin-like domains, a single transmembrane helix, and a cytoplasmic tail containing multiple conserved tyrosine residues phosphorylated by Src family kinase members such as LYN. The protein associates in the membrane with the tetraspanin-like molecule CD81 and the adaptor molecule CD21 (also known as complement receptor 2), forming a coreceptor complex that localizes to membrane microdomains studied in the context of Paul Nurse's membrane biology and lipid raft research in laboratories like Harvard Medical School. CD19 expression begins at the pro-B cell stage in the bone marrow, peaks on mature B cells, and is downregulated upon differentiation into plasma cells under transcriptional control involving factors such as PAX5, EBF1, and BLIMP1. Clinical flow cytometry panels developed by groups at Stanford University and Johns Hopkins Hospital use monoclonal antibodies against CD19 to track B cell populations in peripheral blood and lymphoid tissues.

Function in B cell biology

As a coreceptor, CD19 amplifies signaling from the B cell receptor complex to regulate thresholds for activation, proliferation, and survival, influencing outcomes important to adaptive immunity characterized by researchers at National Institutes of Health and Institut Pasteur. CD19 modulates humoral responses including germinal center reactions studied in models popularized by work at Cold Spring Harbor Laboratory and affects class-switch recombination processes investigated by teams at Imperial College London. Loss-of-function mutations in the CD19 locus produce immunodeficiency phenotypes documented in clinical reports from Great Ormond Street Hospital and genetic consortia such as those associated with European Society for Immunodeficiencies. CD19 also contributes to B cell trafficking and interactions with follicular dendritic cells in lymph nodes examined in studies at University of Oxford.

Signaling mechanisms and interactions

Upon antigen engagement, CD19 cytoplasmic tyrosines are phosphorylated by kinases including SYK and LYN, recruiting signaling adaptors such as PI3K regulatory subunits and GRB2, thereby promoting downstream activation of pathways like AKT and MAPK that control cell metabolism and survival; these pathways are extensively mapped in proteomics and phosphoproteomics studies from laboratories at Massachusetts Institute of Technology and European Molecular Biology Laboratory. CD19 function is modulated by interaction with the complement receptor CD21 when bound to opsonized antigen and by association with CD81 which governs membrane localization; these molecular interactions have been elucidated using structural methods pioneered at Max Planck Institute and cryo-electron microscopy facilities at EMBL. Negative regulation of CD19 signaling involves phosphatases such as PTPN22 and SHP-1, and ubiquitin ligases characterized in studies from University of Cambridge, contributing to feedback control relevant to autoimmunity research performed at Karolinska Institutet.

Role in disease and diagnosis

Aberrant CD19 expression or genetic defects alter B cell development and immune competence, manifesting in conditions reported at centers like Cleveland Clinic and registries coordinated by World Health Organization collaborators; congenital CD19 deficiency leads to hypogammaglobulinemia and recurrent infections. CD19 is retained on most B cell malignancies including B-cell acute lymphoblastic leukemia and many forms of diffuse large B-cell lymphoma, providing a robust diagnostic marker used in panels at Memorial Sloan Kettering Cancer Center and prognostic studies published in journals associated with American Society of Hematology. Paradoxically, CD19-mediated signaling can contribute to oncogenic processes via PI3K/AKT pathway activation, a mechanism investigated in translational programs at MD Anderson Cancer Center and the National Cancer Institute.

Therapeutic targeting and clinical applications

CD19 is a primary antigenic target for cellular and antibody-based therapies; chimeric antigen receptor (CAR) T cell therapies developed at institutions such as University of Pennsylvania (notably the work leading to products commercialized by Novartis and Kite Pharma) have produced durable remissions in refractory B-cell malignancies. Monoclonal antibodies and bispecific T-cell engagers targeting CD19, advanced by commercial and academic partnerships including Roche and Amgen, are used in clinical trials coordinated through networks like European Society for Medical Oncology and National Comprehensive Cancer Network. Therapeutic strategies must manage on-target B cell aplasia and adverse effects such as cytokine release syndrome characterized by treatment teams at Fred Hutchinson Cancer Center and mitigation protocols developed in guidelines from American Society for Transplantation and Cellular Therapy.

Research tools and experimental models

CD19-specific reagents—monoclonal antibodies, fluorescent conjugates, and genetic knockouts—are standard tools used in flow cytometry platforms produced by companies like BD Biosciences and in murine models engineered by groups at The Jackson Laboratory to study B lineage development. Conditional Cd19 knockout mice and humanized mouse xenograft models are employed in preclinical evaluation of CAR constructs at centers such as Children's Hospital of Philadelphia and Broad Institute. Single-cell transcriptomics and CRISPR screens leveraging technologies from 10x Genomics and Broad Institute facilities have refined understanding of CD19 regulation and resistance mechanisms encountered during therapy, informing iterative designs in biotech incubators at Stanford Biodesign and translational cores at Harvard Medical School.

Category:Immune system proteins